Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy.
Br J Haematol. 2009 Dec;147(5):681-5. doi: 10.1111/j.1365-2141.2009.07893.x. Epub 2009 Sep 4.
Although imatinib may be effective in hypereosinophilic syndromes, the exact response kinetics are not known. Imatinib was administered at 100-400 mg/d each week in a 12-week response-oriented schedule, targeting a complete clinical and haematological remission (CR). CR was achieved in 11/23 patients (6/6 with FIP1L1-PDGRFA rearrangement and 5/17 without, P = 0.006), most after 2 weeks of 100 mg/d imatinib. The maximum imatinib dose had no effect in early unresponsive patients. Low-dose, short-course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre-defined FIP1L1 rearrangement subset.
尽管伊马替尼在高嗜酸性粒细胞综合征中可能有效，但确切的反应动力学尚不清楚。伊马替尼每周给药 100-400mg/d，采用 12 周的以反应为导向的方案，目标是完全临床和血液学缓解（CR）。23 例患者中有 11 例（6 例具有 FIP1L1-PDGRFA 重排，5 例无重排，P=0.006）达到 CR，大多数在伊马替尼 100mg/d 治疗 2 周后达到。在早期无反应的患者中，最大伊马替尼剂量没有效果。低剂量、短疗程伊马替尼可能代表一种合理的选择，无论是在预先定义的 FIP1L1 重排亚组内还是外，都可以识别出有反应的病例。
